Fairvalue-Calculator Fairvalue-Calculator
EN DE

Shanghai Runda Medical Technology Co (603108) Fair Value & Analysis

Healthcare · CN · Market cap 6.3B CNY

Price¥10.51
Fair Value¥17.40
Upside+65.6%
Quality83/100
Evidence: Medium Range ¥9.85 – ¥28.29

Analysis

Shanghai Runda Medical Technology Co (603108) currently trades at ¥10.51, while our model-based Fair Value estimate is ¥17.40 — implying the stock looks roughly 65.6% undervalued today. We read business quality at 83/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Shanghai Runda Medical Technology Co., Ltd. provides medical laboratory services primarily in China. It offers laboratory design/renovation and SIMS stock information management system; medical solutions to help healthcare professionals; various customized laboratory management solutions; professional technical services; and logistic services. The company also engages in the research and development, manufacturing, sale, and service of in vitro diagnostic products, including reagents and other consumables. In addition, it is involved in the software development; provision of information system integration and consulting services; sale of chemicals and medical devices; rental services; maintenance of electronic and mechanical equipment; import and export of technology; general cargo warehousing and road freight transportation; and wholesale of medicine. The company was incorporated in 1999 and is headquartered in Shanghai, China.

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -30% Danaher Corporation (DHR) -37% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -53% Lonza Group (LZAGY) -59% Agilent Technologies, Inc (A) -50%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.